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Abstract 
A versatile and general route has been developed for the asymmetric synthesis of a wide family of 3-
methyl-3,4-dihydro-2H-benzo[b][1,4]oxazines bearing different pattern substitutions in the aromatic 
ring. While hydrolases were not suitable for the resolution of these racemic cyclic nitrogenated amines, 
alternative chemoenzymatic strategies were designed through independent pathways leading to both 
amine antipodes. On one hand, the bioreduction of 1-(2-nitrophenoxy)propan-2-ones allowed the 
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recovery in high yields of the enantiopure (S)-alcohols using the alcohol dehydrogenase from 
Rhodococcus ruber (ADH-A), while the evo-1.1.200 ADH led to their counterpart (R)-enantiomers with 
also complete selectivity and quantitative conversions. Alternatively, lipase-catalyzed acetylation of 
these racemic alcohols and the complementary hydrolysis of the acetate analogues gave access to the 
corresponding optically enriched products with high stereodiscrimination. Particularly attractive was the 
design of a chemoenzymatic strategy in 6 steps for the production of (S)-(–)-7,8-difluoro-3-methyl-3,4-
dihydro-2H-benzo-[b][1,4]oxazine, which is a key precursor of the antimicrobial agent Levofloxacin. 
 
Keywords: Alcohol dehydrogenases/ Asymmetric synthesis/ Benzoxazine/ Levofloxacin / Lipases / 
Stereoselective synthesis 
 
Introduction 
 
Benzoxazines are privileged cyclic subunits found in a wide range of biologically active molecules 
with antibacterial, anticancer, antifungal and antimicrobial properties,1 but also serve as synthetic 
building blocks for the formation of more complex structures with relevant medical applications.2 The 
synthesis of achiral and racemic benzoxazines has been extensively reported in the literature,3 
particularly for those bearing the 3,4-dihydro-2H-benzo[b][1,4]oxazine fragment (Figure 1),4 while less 
examples have appeared regarding the development of asymmetric routes towards enantioenriched 
benzoxazines. Optically active 3,4-dihydro-2H-benzo[b][1,4]oxazines have been mostly synthesized 
through asymmetric metal-catalyzed transfer hydrogenation5 or hydrosilylation of imines,6 
organocatalytic additions7 and broadly by using chemical kinetic resolutions of the racemic 
benzoxazines with optically active acyl chlorides8 or palladium catalyzed couplings.9 
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Figure 1. Chemical structure of the 3,4-dihydro-2H-benzo[b][1,4]oxazine subunit (left) and 
Levofloxacin, (right). 
 
Certainly, one of the most targeted benzoxazine derivatives is Levofloxacin (Figure 1), which is a 
potent fluoroquinolone antibacterial agent, currently approved for the treatment of different human 
diseases such as pneumonia, acute bacterial sinusitis, urinary tract infections and acute pyelonephritis.10 
Chemical asymmetric strategies have been successfully carried out for the synthesis of this drug and 
other related non fluorinated analogues,5a,11 the main efforts focused in the production of (S)-(–)-7,8-
difluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine, which serves as adequate synthetic building 
block for the total synthesis of Levofloxacin. 
Biocatalytic methods represent elegant and sustainable strategies for the production of enantiopure 
compounds under mild reaction conditions. In the last decades many organic chemists have incorporated 
the use of enzymes in their toolbox,12 lipases and alcohol dehydrogenases being currently the most 
employed catalysts for their use in industrial applications, although other such as transaminases are 
nowadays receiving great attention.13 Enzymes have been identified as particularly useful for the design 
of valuable synthetic routes towards the synthesis of enantiopure amines by means of the use of lipases, 
transaminases, monoamine oxidases and imine reductases among others.14 In this context, hydrolases 
are valuable hydrolytic enzymes which can also catalyzed acylation reaction for the selective formation 
of amines through kinetic resolution processes.15 Among the hydrolytic enzymes, lipases have attracted 
great attention due to their selective action in the asymmetric synthesis of a wide range of heterocyclic 
nitrogenated compounds.16 Surprisingly, the production of optically enriched benzoxazine derivatives is 
limited to pig liver esterase-catalyzed hydrolytic approaches, finding moderate selectivity values.17 
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Herein, we wish to report the versatility of enzymes for the production of benzoxazine derivatives by 
the development of robust chemoenzymatic methods, lipases and oxidoreductases being satisfactorily 
used for the production of target cyclic nitrogenated compounds with good yields and excellent 
enantiomeric excess values. Special attention will be paid to the asymmetric synthesis of a valuable 
precursor of Levofloxacin. 
 
Results and discussion 
 
To explore new asymmetric routes for the synthesis of benzoxazine derivatives, the 3-methyl-3,4-
dihydro-2H-benzo[b][1,4]oxazine (4a) was selected as a model for enzymatic activity screening. The 
synthesis of the racemate was performed by O-alkylation of 2-nitrophenol (1a) using chloroacetone (2) 
in the presence of potassium bromide, sodium hydrogencarbonate and tributylmethylammonium 
chloride, followed by a palladium catalyzed hydrogenation-cyclization sequence of the nitro ketone 3a 
that allowed the isolation of (±)-4a in 75% overall yield. Because of the good levels of activity and 
stereoselectivity found for lipases in the classical kinetic resolution of secondary cyclic amines,18 a 
panel of commercially available lipases (Candida antarctica lipase types A and B, porcine pancreas 
lipase, Candida rugosa lipase and Pseudomonas cepacia lipase) was used for the alkoxycarbonylation 
of 4a. Unfortunately, no significant activity was observed when using different allyl carbonates in 
methyl tert-butyl ether (MTBE) as solvent. 
 
Scheme 1. Synthesis of racemic benzoxazine 4a for the study of its kinetic resolution. 
 
Searching for an alternative strategy, we decided to take advantage from the previous preparation of 
 5 
nitro ketone 3a. Then, three independent strategies were undertaken (a) the non selective reduction of 
the ketone 3a to the racemic alcohol 5a followed by its classical kinetic resolution through lipase-
catalyzed acylative processes; (b) the chemical acetylation of the so-obtained racemic alcohol to analyze 
in depth the complementary lipase-catalyzed hydrolytic process; (c) the selective bioreduction of the 
prochiral ketone 3a using alcohol dehydrogenases. For these studies, a series of benzoxazine precursors 
bearing different pattern substitutions such as a fluorine atom, a methoxy group or a methyl 
functionality along the aromatic ring were chemically prepared through an efficient chemical route as 
depicted in Scheme 2. This includes the O-alkylation of 2-nitrophenols (1a-d), reduction of ketones 3a-
d with sodium borohydride and later acetylation with acetic anhydride in the presence of DMAP and 
triethylamine, affording the corresponding racemic acetates 6a-d in good overall yields. 
 
Scheme 2. Chemoenzymatic synthesis of nitro ketones 3a-d, alcohols 5a-d and acetates 6a-d. 
 
The lipase-catalyzed acetylation of alcohols 5a-d was firstly considered, searching for a suitable 
lipase that was able to produce the corresponding alcohols and acetates in high optical purity (Table S1). 
The alcohol 5a was selected as model substrate finding Rhizomucor miehei lipase in immobilized form 
(RML IM) as an ideal candidate leading to a 48% conversion in MTBE after 5 h with a 94% ee for the 
(R)-acetate and 89% ee for the remaining (S)-alcohol. Other lipases such as Candida antarctica lipase 
type A (CAL-A) and Pseudomonas cepacia (PSL-C I) displayed poor selectivities while Candida 
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antarctica lipase type B (CAL-B) did not shown significant activity. From a set of solvents the best 
results were found with MTBE and toluene (Table 1, entries 1 and 2), so next the extension to alcohols 
5b-d was performed. A similar trend was observed achieving the highest rates for the reactions carried 
out in MTBE (entries 3, 5 and 7), while the better selectivities were attained in toluene (entries 4, 6 and 
8). MTBE was revealed to be the solvent of choice since the conversion values were lower in toluene 
(27-49%), and in addition the acetate optical purity begins to decrease at longer periods of time (data not 
shown). 
Table 1. Enzymatic kinetic resolution of alcohols 5a-d using RML IM (1:1 w/w) and 3 equivalents of 
vinyl acetate (7) in dry MTBE or toluene at 30 ºC and 250 rpm. 
 
Entry Ra Solvent t (h) eep (%)
b ees (%)
b c (%)c Ed 
1 5a (H) MTBE 5 94 (45) 89 (44) 48 103 
2 5a (H) Toluene 29.5 97 92 49 188 
3 5b (4-F) MTBE 5 95 (47) 91 (48) 49 117 
4 5b (4-F) Toluene 20 99 37 27 >200 
5 5c (4-OMe) MTBE 5 94 (47) 93 (48) 50 102 
6 5c (4-OMe) Toluene 20 >99 73 42 >200 
7 5d (5-Me) MTBE 7 93 (46) 94 (48) 50 103 
8 5d (5-Me) Toluene 20 >99 45 31 >200 
a Substitution in brackets. 
b Determined by HPLC. Isolated yields in parentheses. 
c c = ees/(ees + eep). 
d E= ln[(1-c)(1-eep)]/ln[(1-c)(1+eep)].
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Alternatively, we decided to study the lipase-catalyzed hydrolysis of the corresponding acetates. The 
results are summarized in Table 2. Since the water content is a decisive parameter for the enzymatic 
activity, the amount of water was studied using as reference the substrate 6a without substitutions in the 
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aromatic ring (entries 1-3). In all cases, an excellent selectivity was observed, obtaining the 
complementary alcohol (R)-5a and the acetate (S)-6a in comparison with the lipase-catalyzed 
acetylation reaction. The reaction with 5 equivalents of hydrolytic agent led to a 48% conversion (entry 
1) while notably, an increase in the amount of water led to slower kinetics but also with excellent 
stereoselectivity (21-35%, entries 2 and 3). Similar good results were obtained when extending the 
methodology to other substituted benzoxazine derivatives using 5 equivalents of water (entries 4-6). 
 
Table 2. Enzymatic kinetic resolution of acetates 6a-d using RML IM (1:1 w/w) in the presence of 
water using MTBE as solvent at 30 ºC and 250 rpm after 52 h. 
 
Entry Substratea H2O (equiv) eep (%)
b ees (%)
b c (%)c Ed 
1 6a (H) 5 98 (44) 92 (41) 48 >200 
2 6a (H) 10 99 53 35 >200 
3 6a (H) 20 >99 27 21 >200 
4 6b (4-F) 5 96 (44) 97 (48) 50 >200 
5 6c (4-OMe) 5 >99 (46) 91 (47) 48 >200 
6 6d (5-Me) 5 >99 (47) 94 (48) 49 >200 
a Substitution in brackets. 
b Determined by HPLC. Isolated yields in parentheses. 
c c = ees/(ees + eep). 
d E= ln[(1-c)(1-eep)]/ln[(1-c)(1+eep)].
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Finally, bioreduction experiments were considered based on the access towards the final product in 
theoretically 100% yield. Oxidoreductases with opposite stereopreferences were employed in order to 
develop suitable routes for both alcohol antipodes. Thus, a set composed of Prelog alcohol 
dehydrogenases20 as the one from ADH-A from Rhodococcus ruber (ADH-A), Candida parapsilosis 
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(ADH-CP) and Baker′s yeast (BY), but also anti-Prelog enzymes like Lactobacillus brevis (ADH-LB), 
Lactobacillus kefir (ADH-LK) and evo-1.1.200 ADH were screened in a 50 mM TRIS.HCl buffer pH 
7.5 using a suitable cofactor recycling system when required (Table 3). For the Prelog enzymes high to 
excellent selectivities were found towards the formation of the (S)-alcohol 5a (entries 1-3), notably the 
ADH-A showed a complete conversion and complete selectivity after 24 h (entry 1). On the other hand, 
for the synthesis of (R)-5a, the ADH-LK reduced completely the ketone obtaining the alcohol with very 
high enantiomeric excess (entry 4), while a 91% conversion was achieved in the production of the 
enantiopure alcohol when using ADH-LB (entry 5). The best result for the production of (R)-5a was 
observed with the evo-1.1.200 ADH (entry 6), obtaining the target alcohol in quantitative conversion. 
Table 3. Bioreduction of nitro ketone 3a for the production of optically active alcohol 5a in TRIS.HCl 
buffer pH 7.5 after 24 h at 30 ºC. 
 
Entry Enzyme Cofactor c (%)a ee (%)a 
1 ADH-A NADH >99 99 (S) 
2 ADH-CP NADH 8 99 (S) 
3 BY ---- >99 86 (S) 
4 ADH-LK NADPH >99 96 (R) 
5 ADH-LB NADPH 91 >99 (R) 
6 evo-1.1.200 NADH >99 >99 (R) 
a Conversion and enantiomeric excess values 
calculated by 1H NMR or HPLC measurements of 
the reaction crude. Absolute configurations appear in 
parentheses. 
 
An efficient scale-up of the optimum ADH-catalyzed processes was successfully achieved for both a 
Prelog (ADH-A) and an anti-Prelog enzyme (evo-1.1.200 ADH), leading to the desired (S)- and (R)-
alcohol in quantitative conversion and 85% and 99% isolated yields, respectively after a simple 
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extraction protocol (Table 4, entries 1 and 2). This methodology was satisfactorily extended to the 
bioreduction of ketones 3b-d (entries 3-8). Both alcohol dehydrogenases led to full conversions, the 
ADH-A producing the enantiopure alcohols (S)-5b-d with very high yields (88-93% yield, entries 3, 5 
and 7), while the evo-1.1.200 ADH led to the enantiopure (R)-alcohols in 78-88% yield (entries 4, 6 and 
8). In this manner, the isolated yields were improved in comparison with the lipase-catalyzed 
transformations that are limited to a theoretically 50% yield due to the inherent limitations of kinetic 
resolution procedures. 
Table 4. Bioreduction of nitro ketones 3a-d in TRIS.HCl buffer pH 7.5 after 24 h at 30 ºC. 
 
Entry Enzyme 3 c (%)a ee (%)a 
1 ADH-A 3a >99 (85) 99 (S) 
2 evo-1.1.200 3a >99 (99) >99 (R) 
3 ADH-A 3b >99 (89) >99 (S) 
4 evo-1.1.200 3b >99 (87) >99 (R) 
5 ADH-A 3c >99 (88) >99 (S) 
6 evo-1.1.200 3c >99 (88) >99 (R) 
7 ADH-A 3d >99 (93) >99 (S) 
8 evo-1.1.200 3d >99 (78) >99 (R) 
a Conversion and enantiomeric excess values 
calculated by 1H NMR or HPLC measurements of 
the reaction crude. Absolute configurations and 
isolated yields appear in parentheses. 
 
A four-step sequence was designed for the production of racemic and enantiopure benzoxazines 10a-
d, occurring without any racemization of the intermediates or the final products (Scheme 3). Starting 
from the (S)-alcohols 5a-d, the proposed synthesis began with the palladium catalyzed hydrogenation of 
the nitro functionality forming the corresponding amino alcohol (S)-8a-d, which was activated prior to 
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the cyclization under Mitsunobu condition reactions to avoid mixture of products as occurs using the 
free amine or when additional catalysts were employed as ZnCl2 with related amino alcohols, for 
example 8e.21 This process occurred with inversion of the absolute configuration, yielding the tosylated 
benzoxazine derivative (R)-10a-d. As an example, the final deprotection of the activated amine 10a with 
the tosyl group using magnesium in refluxing methanol allowed the recovery of the (R)-3-methyl-3,4-
dihydro-2H-benzo[b][1,4]oxazine (4a) in 80% isolated yield after 2 h. 
 
Scheme 3. Chemical synthesis of protected enantiopure benzoxazines 10a-d. 
 
Once that a powerful chemoenzymatic strategy was developed for the asymmetric synthesis of a 
representative number of 3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine derivatives, efforts were 
focused on the development of an efficient and selective preparation of the Levofloxacin precursor (4e, 
7,8-difluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine). For that reason, a similar route was 
attempted starting from commercially available 2,3-difluoro-6-nitrophenol (1e) as depicted in Scheme 4. 
Its O-alkylation proceeded in 85% yield for the formation of the nitro ketone 3e, which was subjected to 
the ADH-A catalyzed bioreduction leading to enantiopure (S)-5e after 24 h in 91% isolated yield using a 
TRIS.HCl buffer pH 7.5. For the preparation of its counterpart (R)-5e the use of evo-1.1.200 was 
attempted, finding a complete selectivity although its structural isomer 2-(2,3-difluoro-6-
nitrophenoxy)propan-1-ol (11) was also found as a side product. For that reason, the bioreduction was 
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carried out at different pHs, minimizing the formation of 11 at lower pH values (6-6.5), yielding the 
alcohol (R)-5e in 94% isolated yield after 24 h at 30 ºC in a TRIS.HCl buffer pH 6. It must be mentioned 
that a (R)-configuration is required for the formation of the Levofloxacin, so the use of evo-1.1.200 
seems to be an excellent tool for the introduction of the desired chirality. 
 
Scheme 4. Chemoenzymatic synthetic alternatives for the production of the enantiopure alcohol (R)-5e 
and the corresponding Levofoxacin precursor (S)-4e. 
 
In addition, the lipase-catalyzed hydrolysis of the racemic acetate 6e was attempted, which would 
give direct access to the desired (R)-alcohol 5e. Firstly, the chemical reduction of the ketone 3e was 
initially performed with sodium borohydride. In this case, the unexpected formation of a (61:39) 
mixture of the desired alcohol (±)-5e and the structural isomer 2-(2,3-difluoro-6-nitrophenoxy)propan-
1-ol (11) was observed. The formation of this side-product was almost suppressed using a mild reducing 
agent as the ammonia borane complex,22 thus avoiding a basic reaction medium but also a basic work-
up in the reaction, recovering 5e in 78% yield after 1 h at 30 ºC. Then, the alcohol was chemically 
acetylated in 93% yield using acetic anhydride, to later explore its RML IM-catalyzed hydrolysis. After 
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53 h a total selectivity towards the formation of the (R)-alcohol was attained, obtaining the (S)-acetate 
6e in 84% ee and the desired enantiopure (R)-alcohol 5e in 45% isolated yield. 
Finally, taking the alcohol (R)-5e, a four step sequence was carried out involving the reduction of the 
nitro functionality, protection of the free amine, cyclization reaction in Mitsunobu condition and N-tosyl 
deprotection, leading to the valuable enantiopure Levofloxacin precursor (S)-4e in good overall yield 
(36%). 
 
Conclusions 
Two different classes of enzymes have efficiently served for the development of the asymmetric 
synthesis of both 3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazines enantiomers. Alcohol 
dehydrogenases and lipases have been identified as good catalysts for the synthesis of valuable optically 
active precursors as key independent features of the synthetic route. The alcohol dehydrogenase from 
Rhodococcus ruber has allowed the selective bioreduction of 1-(2-nitrophenoxy)propan-2-ones with 
complete selectivity towards the quantitative conversion into the (S)-alcohols, while the evo-1.1.200 led 
to the corresponding enantiopure (R)-enantiomers. On the other hand a lipase screening has been carried 
out, finding Rhizomucor miehei lipase as a versatile hydrolase for the development of classical kinetic 
resolutions through complementary acylative and hydrolytic processes. The chemoenzymatic route has 
also served to synthesize a valuable Levofloxacin precursor, which has been isolated in enantiopure 
form after a six-step sequence in good overall yield. 
 
Experimental section 
General procedure for the synthesis of ketones 3a-e. To a solution of the corresponding nitrophenol 
1a-e (3.02 mmol) in toluene (1 mL) chloroacetone (481 L, 6.04 mmol), potassium bromide (43 mg, 
0.36 mmol), sodium hydrogencarbonate (279 mg, 3.32 mmol) and tributylmethylammonium chloride 
solution (75% weight in water, 16 L, 0.065 mmol) were successively added. The mixture was stirred 
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and heated at 65 ºC for 6 h and then additional chloroacetone (120 L, 1.51 mmol) was added. The 
reaction was further heated at 65 ºC for 18 h and after this time water (1 mL) was added. The pH of the 
mixture was adjusted to 6.5-7 at 55-60 ºC by the addition of HCl 1N (between 7-15 drops). The layers 
were separated in a separatory funnel, and the aqueous phase was discarded. Then, an aqueous 5% NaCl 
solution (2 mL) was added to the organic phase and transferred to a round-bottom flask. The resulting 
mixture was vigorously stirred at 55-60 ºC for 10 min. The layers were again separated in a separatory 
funnel, the organic layer was collected, dried over Na2SO4, filtered and the solvent removed by 
distillation under reduced pressure. The resulting crude was washed with toluene to assure the complete 
chloroacetone removal, affording the corresponding pure ketones 3a-e (84-93%). 
1-(2-Nitrophenoxy)propan-2-one (3a). White solid (548 mg, 93% Yield). Rf (40% EtOAc/Hexane): 
0.31. Mp: 68-70 ºC. IR (KBr): 3055, 2987, 2306, 1739, 1724, 1608, 1528, 1357, 1166, 1052, 860 cm-1. 
1H NMR (300.13 MHz, CDCl3):  2.35 (s, 3H), 4.62 (s, 2H), 6.94 (dd, 3JHH = 8.4 Hz, 4JHH = 0.9 Hz, 
1H), 7.03-7.10 (m, 1H), 7.53 (ddd, 3JHH = 8.6, 7.5 Hz, 
4JHH = 1.7 Hz, 1H), 7.87 (dd, 
3JHH = 8.1 Hz, 
4JHH 
= 1.6 Hz, 1H). 13C NMR (75.5 MHz, CDCl3):  27.0 (CH3), 73.8 (CH2), 114.7 (CH), 121.7 (CH), 126.1 
(CH), 134.4 (CH), 140.1 (C), 151.1 (C), 204.4 (C). HRMS (ESI+, m/z): calcd for (C9H9NNaO4)
+ 
(M+Na)+: 218.0424 found: 218.0402. 
1-(4-Fluoro-2-nitrophenoxy)propan-2-one (3b). Light yellow solid (592 mg, 92% Yield). Rf (40% 
EtOAc/Hexane): 0.21. Mp: 82-83 ºC. IR (KBr): 3055, 2987, 2343, 1740, 1723, 1538, 1498, 1420, 1360, 
1204, 1049, 815 cm-1. 1H NMR (400.13 MHz, CDCl3):  2.33 (s, 3H), 4.62 (s, 2H), 6.96 (dd, 3JHH = 9.2 
Hz, 4JFH = 4.2 Hz, 1H), 7.28 (ddd, 
3JHH = 9.3 Hz, 
3JFH = 7.4, 
4JHH = 3.1 Hz, 1H), 7.63 (dd, 
3JFH = 7.7 Hz, 
4JHH = 3.1 Hz, 1H). 
13C NMR (100.6 MHz, CDCl3):  26.9 (CH3), 74.6 (CH2), 113.4 (d, 2JFC = 27.5 Hz, 
CH), 116.7 (d, 3JFC = 7.8 Hz, CH), 121.4 (d, 
2JFC = 23.0 Hz, CH), 139.9 (d, 
3JFC = 6.8 Hz, C), 147.8 (C), 
156.1 (d, 1JFC = 245.6 Hz, C), 204.0 (C). HRMS (ESI
+, m/z): calcd for (C9H8FNNaO4)
+ (M+Na)+: 
236.0330 found: 236.0335. 
1-(4-Methoxy-2-nitrophenoxy)propan-2-one (3c). Yellow solid (578 mg, 85% Yield). Rf (40% 
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EtOAc/Hexane): 0.38. Mp: 80-81 ºC. IR (KBr): 3055, 2987, 2348, 1739, 1718, 1534, 1499, 1430, 1360, 
1224, 1052, 1035, 896, 811 cm-1. 1H NMR (300.13 MHz, CDCl3):  2.31 (s, 3H), 3.80 (s, 3H), 4.57 (s, 
2H), 6.92 (d, 3JHH = 9.2 Hz, 1H), 7.07 (dd, 
3JHH = 9.1 Hz, 
4JHH = 3.1 Hz 1H), 7.39 (d, 
4JHH = 3.1 Hz, 
1H). 13C NMR (75.5 MHz, CDCl3):  27.0 (CH3), 56.3 (CH3), 75.1 (CH2), 110.4 (CH), 117.2 (CH), 
121.0 (CH), 140.4 (C), 145.5 (C), 154.1 (C), 204.9 (C). HRMS (ESI+, m/z): calcd for (C10H11NNaO5)
+ 
(M+Na)+: 248.0529 found: 248.0540. 
1-(5-methyl-2-nitrophenoxy)propan-2-one (3d). Light yellow solid (531 mg, 84% Yield). Rf (40% 
EtOAc/Hexane): 0.41. Mp: 98-99 ºC. IR (KBr): 3056, 1724, 1723, 1608, 1521, 1419, 1348, 1179, 1097, 
1051, 896, 820 cm-1. 1H NMR (300.13 MHz, CDCl3):  2.37 (s, 3H), 2.41 (s, 3H), 4.60 (s, 2H), 6.73 (s, 
1H), 6.90 (d, 3JHH = 8.3 Hz, 1H), 7.85 (d, 
3JHH = 8.3 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  21.8 
(CH3), 26.8 (CH3), 73.7 (CH2), 115.2 (CH), 122.2 (CH), 126.1 (CH), 137.4 (C), 146.3 (C), 151.2 (C), 
204.4 (C). HRMS (ESI+, m/z): calcd for (C10H11NNaO4)
+ (M+Na)+: 232.0580 found: 232.0581. 
1-(2,3-Difluoro-6-nitrophenoxy)propan-2-one (3e). Light yellow solid (593 mg, 85% Yield). Rf 
(40% EtOAc/Hexane): 0.69. Mp: 43-45 ºC. IR (KBr): 3059, 2987, 2924, 1741, 1627, 1597, 1541, 1496, 
1358, 1217, 1070, 813 cm-1. 1H NMR (300.13 MHz, CDCl3):  2.32 (s, 3H), 4.80 (d, 5JFH = 1.3 Hz, 2H), 
7.05 (ddd, 3JHH = 9.3 Hz, 
3JFH = 8.8 Hz,
 4JFH = 7.2 Hz, 1H), 7.72 (ddd, 
3JHH = 9.4 Hz, 
4JFH = 5.2, 
5JFH = 
2.4 Hz, 1H). 13C NMR (75.5 MHz, CDCl3):  26.4 (CH3), 78.1 (d, 4JFC = 5.3 Hz, CH2), 111.7 (d, 2JFC = 
19.3 Hz, CH), 120.8 (dd, 3JFC = 9.0 Hz,
 4JFC = 4.0 Hz, CH), 140.0 (d,
 3JFC = 3.7 Hz, C), 142.6 (dd, 
2JFC = 
10.9 Hz, 3JFC = 2.9 Hz, C), 144.7 (dd, 
1JFC = 252.9 Hz,
 2JFC = 14.7 Hz, C), 154.1 (dd, 
1JFC = 259.6 Hz,
 
2JFC = 11.6 Hz, C), 203.0 (C). HRMS (ESI
+, m/z): calcd for (C9H7F2NNaO4)
+ (M+Na)+: 254.0235 
found: 254.0249. 
 
Synthesis of racemic 3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (4a). Pd/C (10% weight 
loading, 100 mg) was added to a solution of ketone 3a (2.05 mmol, 400 mg) in methanol (0.02 M, 102.5 
mL) placed in the reaction vessel of a Parr hydrogenator. The air was evacuated and hydrogen was 
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introduced into the system until 4 atm of pressure. The suspension was stirred for 6 h at room 
temperature and afterwards the solvent was evaporated under reduced pressure. The residue was 
dissolved in Et2O (20 mL) and the metal catalyst was filtered off through a diatomaceous earth plug. 
The reaction crude was obtained after solvent evaporation and purified by column chromatography on 
silica gel (20% Et2O/Hexane), affording the racemic benzoxazine 4a (245 mg, 80% Yield). 
Spectroscopical data are in agreement with those previously reported in the literature using a different 
procedure.23 
 
General procedure for the synthesis of racemic nitro alcohols 5a-d. Sodium borohydride (19 mg, 
0.50 mmol) was added to a solution of the corresponding ketone 3a-d (1.00 mmol) in dry MeOH (3.8 
mL) at 0 ºC. The solution was stirred at room temperature for 45 min, quenching the reaction by the 
addition of water (10 mL). MeOH was removed by distillation under reduced pressure and the aqueous 
residue extracted with CH2Cl2 (3 x 10 mL). The organic layers were combined, dried and the solvent 
removed by distillation under reduced pressure, affording the corresponding nitro alcohols 5a-d (87-
94%). 
1-(2-Nitrophenoxy)propan-2-ol (5a). Yellow oil (172 mg, 87% Yield). Rf (40% EtOAc/Hexane): 
0.19. IR (NaCl): 3586, 3440, 3055, 2985, 2937, 2307, 1609, 1526, 1354, 1166, 1020, 860 cm-1. 1H 
NMR (300.13 MHz, CDCl3):  1.25 (d, 3JHH = 6.4 Hz, 3H), 3.03 (br s, 1H), 3.88 (dd, 2JHH = 8.9 Hz, 3JHH 
= 7.5 Hz, 1H), 4.07 (dd, 2JHH = 9.0 Hz,
 3JHH = 3.1 Hz, 1H), 4.12-4.24 (m, 1H), 6.98-7.15 (m, 2H), 7.46-
7.61 (m, 1H), 7.80 (dd, 3JHH = 8.0 Hz, 
4JHH = 1.6 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  18.5 (CH3), 
65.8 (CH), 75.0 (CH2), 115.0 (CH), 120.8 (CH), 125.8 (CH), 134.5 (CH), 139.6 (C), 152.2 (C). HRMS 
(ESI+, m/z): calcd for (C9H11NNaO4)
+ (M+Na)+: 220.0580 found: 220.0609. 
1-(4-Fluoro-2-nitrophenoxy)propan-2-ol (5b). Yellow solid (202 mg, 94% Yield). Rf (40% 
EtOAc/Hexane): 0.26. Mp: 74-76 ºC. IR (KBr): 3586, 3441, 3055, 2984, 2935, 2340, 1534, 1499, 1354, 
1203, 1141, 1022, 815, 786 cm-1. 1H NMR (300.13 MHz, CDCl3):  1.28 (d, 3JHH = 6.4 Hz, 3H), 2.98 
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(br s, 1H), 3.90 (dd, 2JHH = 9.0 Hz,
 3JHH = 7.4 Hz, 1H), 4.10 (dd, 
2JHH = 9.0 Hz,
 3JHH = 3.2 Hz, 1H), 
4.15-4.26 (m, 1H), 7.08 (dd, 3JHH = 9.2 Hz, 
4JFH = 4.3 Hz, 1H), 7.28 (ddd, 
3JHH = 9.4 Hz, 
3JFH = 7.3 Hz, 
4JHH = 3.1 Hz, 1H), 7.60 (dd, 
3JFH = 7.8 Hz, 
4JHH = 3.1 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  18.5 
(CH3), 65.9 (CH), 75.8 (CH2), 113.0 (d, 
2JFH = 27.5 Hz, CH), 116.6 (d, 
3JFH = 7.7 Hz, CH), 121.5 (d, 
2JFH = 22.8 Hz, CH), 139.3 (d, 
3JFC = 8.3 Hz, C), 148.9 (d, 
4JFC = 3.0 Hz, C), 155.5 (d, 
1JFC = 244.3 Hz, 
C). HRMS (ESI+, m/z): calcd for (C9H10FNNaO4)
+ (M+Na)+: 238.0486 found: 238.0500. 
1-(4-Methoxy-2-nitrophenoxy)propan-2-ol (5c). Light orange solid (211 mg, 93% Yield). Rf (40% 
EtOAc/Hexane): 0.18. Mp: 75-77 ºC. IR (KBr): 3576, 3431, 3058, 2964, 2922, 2840, 2343, 1527, 1496, 
1346, 1216, 1040, 817 cm-1. 1H NMR (300.13 MHz, CDCl3):  1.25 (d, 3JHH = 6.4 Hz, 3H), 2.76 (br s, 
1H), 3.80 (s, 3H), 3.81-3.91 (m, 1H), 4.07 (dd, 2JHH = 9.1 Hz,
 3JHH = 3.1 Hz, 1H), 4.12-4.27 (m, 1H), 
7.01 (d, 3JHH = 9.1 Hz, 1H), 7.09 (dd,
 3JHH = 9.1 Hz, 
4JHH = 3.0 Hz, 1H), 7.37 (d, 
4JHH = 3.0 Hz, 1H). 
13C 
NMR (75.5 MHz, CDCl3):  18.5 (CH3), 56.1 (CH3), 66.0 (CH), 76.1 (CH2), 110.0 (CH), 117.1 (CH), 
121.3 (CH), 139.8 (C), 146.6 (C), 153.4 (C). HRMS (ESI+, m/z): calcd for (C10H13NNaO5)
+ (M+Na)+: 
250.0686 found: 250.0711. 
1-(5-Methyl-2-nitrophenoxy)propan-2-ol (5d). Light orange solid (186 mg, 88% Yield). Rf (40% 
EtOAc/Hexane): 0.18. Mp: 53-54 ºC. IR (KBr): 3583, 3435, 3055, 2985, 2935, 1609, 1592, 1517, 1347, 
1182, 1093, 1031, 841 cm-1. 1H NMR (300.13 MHz, CDCl3):  1.26 (d, 3JHH = 6.4 Hz, 3H), 2.37 (s, 
3H), 3.02 (br s, 1H), 3.86 (dd, 2JHH = 9.0 Hz,
 3JHH = 7.6 Hz, 1H), 4.08 (dd, 
2JHH = 9.0 Hz,
 3JHH = 3.2 Hz, 
1H), 4.12-4.25 (m, 1H), 6.79 (d, 3JHH = 8.3 Hz, 1H), 6.84 (s, 1H), 7.76 (d, 
3JHH = 8.3 Hz, 1H). 
13C NMR 
(75.5 MHz, CDCl3):  18.5 (CH3), 22.0 (CH3), 66.0 (CH), 75.2 (CH2), 115.7 (CH), 121.7 (CH), 126.2 
(CH), 137.4 (C), 146.4 (C), 152.6 (C). HRMS (ESI+, m/z): calcd for (C10H13NNaO4)
+ (M+Na)+: 
234.0737 found: 234.0727. 
 
Synthesis of racemic 1-(2,3-difluoro-6-nitrophenoxy)propan-2-ol (5e). Ammonia borane complex 
(24 mg, 0.76 mmol) was added to a solution of ketone 3e (1.51 mmol) in dry THF (4.6 mL) and the 
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mixture was stirred at 30 ºC for 1 h. After this time the reaction was stopped by careful addition at 0 ºC 
of an aqueous HCl 2 M solution until an acidic pH (pH < 3) was achieved. Then, the mixture was 
extracted with CH2Cl2 (3 x 10 mL), the organic layers were combined, dried, filtered and the solvent 
was removed by distillation under reduced pressure. The crude was purified by column chromatography 
on silica gel (10% EtOAc/Hexane), affording the nitro alcohol 5e (275 mg, 78% Yield). Yellow oil. Rf 
(40% EtOAc/Hexane): 0.51. IR (NaCl): 3569, 3439, 3054, 2987, 2360, 2307, 1653, 1539, 1355, 1163, 
1022, 852, 665 cm-1. 1H NMR (300.13 MHz, CDCl3):  1.25 (d, 3JHH = 6.4 Hz, 3H), 2.83 (d, 3JHH = 3.7 
Hz, 1H), 4.10 (ddd, 2JHH = 9.5 Hz, 
3JHH = 7.7 Hz, 
5JFH = 1.9 Hz, 1H), 4.15-4.28 (m, 1H), 4.38 (dt, 
2JHH = 
9.4 Hz, 3JHH = 2.4 Hz, 
5JFH = 2.4 Hz, 1H), 7.01 (ddd,
 3JHH = 9.4 Hz, 
3JFH = 8.8 Hz,
 4JFH = 7.2 Hz, 1H), 
7.72 (ddd, 3JHH = 9.4 Hz,
 4JFH = 5.3, 
5JFH = 2.4 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  18.2 (CH3), 
66.5 (CH), 81.2 (d, 4JFC = 5.7 Hz, CH2), 111.1 (d, 
2JFC = 19.3 Hz,
 CH), 120.9 (dd, 3JFC = 9.2 Hz, 
4JFC = 
4.0 Hz, CH), 139.5 (d, 3JFC = 1.9 Hz, C), 143.8 (dd, 
2JFC = 10.9 Hz,
 3JFC = 2.8 Hz, C), 144.7 (dd, 
1JFC = 
253.0 Hz, 2JFC = 14.3 Hz, C), 154.4 (dd, 
1JFC = 259.6 Hz,
 2JFC = 11.6 Hz, C). HRMS (ESI
+, m/z): calcd 
for (C9H9F2NNaO4)
+ (M+Na)+: 256.0392, found: 256.0390. 
 
General procedure for the synthesis of racemic acetates 6a-e. 4-Dimethylaminopyridine (12 mg, 
0.1 mmol), triethylamine (198 L, 1.42 mmol) and acetic anhydride (90 L, 0.95 mmol) were 
successively added to a solution of the corresponding alcohol 5a-e (0.47 mmol) in dry CH2Cl2 (3.2 mL). 
The reaction was stirred at room temperature for 30 min and after this time the solvent removed by 
distillation under reduced pressure. The crude was purified by column chromatography on silica gel 
(EtOAc/Hexane mixtures), affording the corresponding acetates 6a-e (88-94%). 
1-(2-Nitrophenoxy)propan-2-yl acetate (6a). Intense yellow oil (106 mg, 94% Yield). Rf (40% 
EtOAc/Hexane): 0.41. IR (NaCl): 3055, 2986, 2940, 2343, 1734, 1609, 1528, 1355, 1239, 1091, 1035, 
992, 860 cm-1. 1H NMR (300.13 MHz, CDCl3):  1.38 (d, 3JHH = 6.5 Hz, 3H), 2.06 (s, 3H), 4.12 (d, 3JHH 
= 5.1 Hz, 2H), 5.14-5.53 (m, 1H), 6.96-7.17 (m, 2H), 7.51 (ddd, 3JHH = 9.0, 7.5 Hz, 
4JHH = 1.7 Hz, 1H), 
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7.82 (dd, 3JHH = 8.1 Hz, 
4JHH = 1.6 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  16.6 (CH3), 21.2 (CH3), 
68.3 (CH), 71.4 (CH2), 114.9 (CH), 121.0 (CH), 125.8 (CH), 134.2 (CH), 140.2 (C), 151.9 (C), 170.7 
(C). HRMS (ESI+, m/z): calcd for (C11H13NNaO5)
+ (M+Na)+: 262.0686 found: 262.0708. 
1-(4-Fluoro-2-nitrophenoxy)propan-2-yl acetate (6b). White solid (106 mg, 88% Yield). Rf (40% 
EtOAc/Hexane): 0.67. Mp: 63-64 ºC. IR (KBr): 3055, 2987, 2307, 1738, 1537, 1499, 1373, 1357, 1241, 
1203, 1142, 1083, 1034, 943, 814, 788 cm-1. 1H NMR (300.13 MHz, CDCl3):  1.37 (d, 3JHH = 6.5 Hz, 
3H), 2.05 (s, 3H), 4.11 (d, 3JHH = 5.0 Hz, 2H), 5.18-5.30 (m, 1H), 7.06 (dd,
 3JHH = 9.2 Hz, 
4JFH = 4.3 Hz, 
1H), 7.26 (ddd, 3JHH = 9.3 Hz, 
3JFH = 7.4, 
4JHH = 3.1 Hz, 1H), 7.57 (dd, 
3JFH = 7.7 Hz, 
4JHH = 3.1 Hz, 
1H). 13C NMR (75.5 MHz, CDCl3):  16.6 (CH3), 21.2 (CH3), 68.2 (CH), 72.3 (CH2), 113.0 (d, 2JFH = 
27.4 Hz, CH), 116.7 (d, 3JFH = 7.9 Hz, CH), 121.1 (d, 
2JFH = 22.9 Hz, CH), 139.3 (d, 
3JFC = 9.6 Hz, C), 
148.5 (d, 4JFC = 2.6 Hz, C), 155.7 (d, 
1JFC = 244.6 Hz, C), 170.6 (C). HRMS (ESI
+, m/z): calcd for 
(C11H12FNNaO5)
+ (M+Na)+: 280.0592 found: 280.0613. 
1-(4-Methoxy-2-nitrophenoxy)propan-2-yl acetate (6c). Yellow solid (116 mg, 92% Yield). Rf 
(40% EtOAc/Hexane): 0.46. Mp: 55-56 ºC. IR (KBr): 3055, 2986, 2307, 1734, 1533, 1499, 1373, 1354, 
1243, 1041, 812 cm-1. 1H NMR (300.13 MHz, CDCl3):  1.35 (d, 3JHH = 6.5 Hz, 3H), 2.06 (s, 3H), 3.80 
(s, 3H), 4.07 (d, 3JHH = 4.8 Hz, 2H), 5.16-5.28 (m, 1H), 7.01 (d, 
3JHH = 9.1 Hz, 1H), 7.07 (dd,
 3JHH = 9.1 
Hz, 4JHH = 3.0 Hz, 1H), 7.34 (d, 
4JHH = 2.9 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  16.6 (CH3), 21.2 
(CH3), 56.2 (CH3), 68.5 (CH), 72.6 (CH2), 109.9 (CH), 117.4 (CH), 120.8 (CH), 140.5 (C), 146.2 (C), 
153.6 (C), 170.7 (C). HRMS (ESI+, m/z): calcd for (C12H15NNaO6)
+ (M+Na)+: 292.0792 found: 
292.0796. 
1-(5-Methyl-2-nitrophenoxy)propan-2-yl acetate (6d). White solid (107 mg, 90% Yield). Rf (40% 
EtOAc/Hexane): 0.63. Mp: 76-77 ºC. IR (KBr): 3054, 2987, 2306, 1734, 1609, 1521, 1423, 1093, 1040 
cm-1. 1H NMR (300.13 MHz, CDCl3):  1.39 (d, 3JHH = 6.5 Hz, 3H), 2.06 (s, 3H), 2.40 (s, 3H), 4.11 (d, 
3JHH = 5.1 Hz, 2H), 5.22-5.31 (m, 1H), 6.83 (dd, 
3JHH = 8.3 Hz, 
4JHH = 0.7 Hz, 1H), 6.86 (s, 1H), 7.77 
(d, 3JHH = 8.2 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  16.7 (CH3), 21.2 (CH3), 22.0 (CH3), 68.4 (CH), 
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71.4 (CH2), 115.5 (CH), 121.7 (CH), 126.0 (CH), 137.9 (C), 145.9 (C), 152.2 (C), 170.7 (C). HRMS 
(ESI+, m/z): calcd for (C12H15NNaO5)
+ (M+Na)+: 276.0842 found: 276.0856. 
1-(2,3-Difluoro-6-nitrophenoxy)propan-2-yl acetate (6e). Intense yellow oil (120 mg, 93% Yield). 
Rf (40% EtOAc/Hexane): 0.68. IR (NaCl): 3447, 3059, 2988, 2942, 2886, 2343, 1739, 1627, 1541, 
1495, 1357, 1237, 1020, 813 cm-1. 1H NMR (300.13 MHz, CDCl3):  1.33 (d, 3JHH = 6.6 Hz, 3H), 2.03 
(s, 3H), 4.23 (ddd, 2JHH = 10.3 Hz, 
3JHH = 5.9 Hz, 
5JFH = 0.9 Hz, 1H), 4.33 (ddd, 
2JHH = 10.3 Hz, 
3JHH = 
3.4 Hz, 5JFH = 1.0 Hz, 1H), 5.16-5.28 (m, 1H), 7.01 (td,
 3JHH = 9.1 Hz, 
3JFH = 9.1 Hz,
 4JFH = 7.2 Hz, 1H), 
7.66 (ddd, 3JHH = 9.4 Hz,
 4JFH = 5.2 Hz, 
5JFH = 2.4 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  16.1 
(CH3), 21.0 (CH3), 68.8 (CH), 77.2 (d, 
4JFC = 5.2 Hz, CH2), 111.4 (d, 
2JFC = 19.4 Hz,
 CH), 120.4 (dd, 
3JFC = 9.1 Hz, 
4JFC = 4.1 Hz, CH), 140.3 (d, 
3JFC = 2.2 Hz, C), 143.4 (dd, 
2JFC = 9.7 Hz,
 3JFC = 4.41 Hz, 
C), 144.9 (dd, 1JFC = 253.6 Hz,
 2JFC = 14.2 Hz, C), 154.0 (dd, 
1JFC = 259.0 Hz,
 2JFC = 11.3 Hz, C), 170.5 
(C). HRMS (ESI+, m/z): calcd for (C11H11F2NNaO5)
+ (M+Na)+: 298.0497 found: 298.0528. 
 
General procedure for the synthesis of racemic and optically active amino alcohols 8a-e. A 
hydrogen atmosphere was done using a hydrogen balloon connected to a round-bottom flask, which 
contains a suspension of the corresponding nitro alcohol 5a-e (2.50 mmol) and PtO2 (150 mg, 0.66 
mmol) in dry MeOH (14 mL). The resulting suspension was stirred at room temperature overnight and 
then the reaction was stopped by filtering the mixture through a diatomaceous earth plug. The solvent 
was removed by distillation under reduced pressure and the crude purified by column chromatography 
on silica gel (EtOAc/Hexane mixtures), affording the corresponding amino alcohols 8a-e (65-98%). 
1-(2-Aminophenoxy)propan-2-ol (8a). White solid (397 mg, 95% Yield). Rf (40% EtOAc/Hexane): 
0.16. Mp: 66-67 ºC. IR (KBr): 3391, 3054, 2986, 2924, 2340, 1653, 1558, 1506, 1219, 1154 cm-1. 1H 
NMR (300.13 MHz, CD3OD):  1.30 (d, 3JHH = 6.4 Hz, 3H), 3.83 (dd, 2JHH = 9.7 Hz, 3JHH = 6.9 Hz, 
1H), 3.94 (dd, 2JHH = 9.7 Hz,
 3JHH = 3.7 Hz, 1H), 4.16 (dquint, 
3JHH = 6.5, 3.7 Hz, 1H), 4.91 (br s, 3H), 
6.66-6.75 (m, 1H), 6.75-6.90 (m, 3H). 13C NMR (75.5 MHz, CD3OD):  19.5 (CH3), 67.1 (CH), 74.7 
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(CH2), 112.9 (CH), 117.0 (CH), 119.8 (CH), 122.3 (CH), 137.8 (C), 148.4 (C). HRMS (ESI
+, m/z): 
calcd for (C9H14NO2)
+ (M+H)+: 168.1019 found: 168.1020. []D20 +37.0 (c 0.3, EtOH) [for (S)-8a in 
>99% ee]. 
1-(2-Amino-4-fluorophenoxy)propan-2-ol (8b). Brown solid (444 mg, 96% Yield). Rf (40% 
EtOAc/Hexane): 0.16. Mp: 119-121 ºC. IR (KBr): 3391, 3054, 2985, 2933, 2341, 1623, 1513, 1218, 
1160, 1035, 970, 842 cm-1. 1H NMR (400.13 MHz, CDCl3):  1.25 (d, 3JHH = 6.4 Hz, 3H), 3.77 (br s, 
3H), 3.78 (dd, 2JHH = 9.6 Hz,
 3JHH = 7.8 Hz, 1H), 3.90 (dd, 
2JHH = 9.7 Hz,
 3JHH = 3.0 Hz, 1H), 4.06-4.25 
(m, 1H), 6.36 (ddd, 3JHH = 8.6 Hz, 
3JFH = 8.6 Hz,
 4JHH = 2.9 Hz, 1H), 6.43 (dd, 
3JFH = 9.8 Hz, 
4JHH = 2.9 
Hz, 1H), 6.68 (dd, 3JHH = 8.8 Hz, 
4JFH = 5.1 Hz, 1H). 
13C NMR (100.6 MHz, CDCl3):  19.0 (CH3), 66.4 
(CH), 75.1 (CH2), 102.6 (d, 
2JFH = 26.7 Hz, CH), 103.9 (d, 
2JFH = 23.0 Hz, CH), 113.6 (d, 
3JFH = 10.0 
Hz, CH), 138.0 (d, 3JFC = 11.0 Hz, C), 142.5 (C), 158.2 (d, 
1JFC = 237.3 Hz, C). HRMS (ESI
+, m/z): 
calcd for (C9H13FNO2)
+ (M+H)+: 186.0925 found: 186.0941. []D20 +21.6 (c 0.7, EtOH) [for (S)-8b in 
>99% ee]. 
1-(2-Amino-4-methoxyphenoxy)propan-2-ol (8c). Light yellow solid (483 mg, 98% Yield). Rf (40% 
EtOAc/Hexane): 0.10. Mp: 75-76 ºC. IR (KBr): 3583, 3391, 3054, 2986, 2340, 1623, 1516, 1419, 1220, 
1168, 962 cm-1. 1H NMR (400.13 MHz, CDCl3):  1.22 (d, 3JHH = 6.5 Hz, 3H), 3.68 (br s, 3H), 3.70 (s, 
3H), 3.75 (dd, 2JHH = 9.6 Hz,
 3JHH = 7.8 Hz, 1H), 3.87 (dd, 
2JHH = 9.7 Hz,
 3JHH = 3.1 Hz, 1H), 4.07-4.22 
(m, 1H), 6.22 (dd, 3JHH = 8.7 Hz, 
4JHH = 2.9 Hz, 1H), 6.30 (d,
 4JHH = 2.9 Hz, 1H), 6.69 (d, 
3JHH = 8.7 Hz, 
1H). 13C NMR (100.6 MHz, CDCl3):  18.9 (CH3), 55.5 (CH3), 66.3 (CH), 74.4 (CH2), 102.5 (CH), 
102.6 (CH), 114.2 (CH), 137.8 (C), 140.9 (C), 155.0 (C). HRMS (ESI+, m/z): calcd for (C10H16NO3)
+ 
(M+H)+: 198.1125 found: 198.1135. []D20 +23.2 (c 0.5, EtOH) [for (S)-8c in >99% ee]. 
1-(2-Amino-5-methylphenoxy)propan-2-ol (8d). Light pink solid (421 mg, 93% Yield). Rf (40% 
EtOAc/Hexane): 0.15. Mp: 76-78 ºC. IR (KBr): 3402, 3054, 2985, 2929, 2523, 2307, 1592, 1520, 1420, 
1152, 1132, 1041, 812 cm-1. 1H NMR (400.13 MHz, CD3OD):  1.26 (d, 3JHH = 6.5 Hz, 3H), 2.21 (s, 
3H), 3.78 (dd, 2JHH = 9.6 Hz,
 3JHH = 6.9 Hz, 1H), 3.88 (dd, 
2JHH = 9.7 Hz,
 3JHH = 3.7 Hz, 1H), 4.11 
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(dquint, 3JHH = 6.5, 3.8 Hz, 1H), 4.86 (br s, 3H), 6.56 (d, 
3JHH = 7.8 Hz, 1H), 6.64 (s, 1H), 6.66 (d, 
3JHH 
= 7.8 Hz, 1H). 13C NMR (100.6 MHz, CD3OD):  19.5 (CH3), 21.1 (CH3), 67.1 (CH), 74.7 (CH2), 113.8 
(CH), 117.2 (CH), 122.5 (CH), 129.6 (C), 134.8 (C), 148.4 (C). HRMS (ESI+, m/z): calcd for 
(C10H16NO2)
+ (M+H)+: 182.1176 found: 182.1173. []D20 +12.5 (c 0.6, EtOH) [for (S)-8d in >99% ee]. 
1-(6-Amino-2,3-difluorophenoxy)propan-2-ol (8e). Yellow solid (330 mg, 65% Yield). Rf (40% 
EtOAc/Hexane): 0.25. Mp: 56-58 ºC. IR (KBr): 3398, 3054, 2986, 1653, 1559, 1507, 1490, 1419, 1165, 
1047, 896 cm-1. 1H NMR (400.13 MHz, CDCl3):  1.19 (d, 3JHH = 6.4 Hz, 3H), 3.61 (br s, 3H), 3.83 (dd, 
2JHH = 10.8 Hz, 
3JHH = 8.8 Hz, 1H), 4.03-4.16 (m, 2H), 6.39 (ddd, 
3JHH = 9.0 Hz,
 4JFH = 4.8, 
5JFH = 2.3 
Hz, 1H), 6.70 (ddd, 3JFH = 9.9 Hz,
 3JHH = 9.0 Hz,
 4JFH = 8.1 Hz, 1H). 
13C NMR (100.6 MHz, CDCl3):  
18.5 (CH3), 66.6 (CH), 79.3 (d, 
4JFC = 3.3 Hz, CH2), 109.6 (dd, 
3JFC = 6.9 Hz,
 4JFC = 3.2 Hz,
 CH), 111.4 
(d, 2JFC = 17.8 Hz, CH), 135.5 (dd, 
2JFC = 10.4 Hz,
 3JFC = 1.3 Hz, C), 136.8 (dd, 
3JFC = 2.7 Hz,
 4JFC = 1.2 
Hz, C), 144.7 (dd, 1JFC = 239.0 Hz,
 2JFC = 11.3 Hz, C), 144.9 (dd, 
1JFC = 247.1 Hz,
 2JFC = 14.6 Hz, C). 
HRMS (ESI+, m/z): calcd for (C9H12F2NO2)
+ (M+H)+: 204.0831 found: 204.0857. []D20 -22.4 (c 0.7, 
EtOH) [for (R)-8e in >99% ee]. 
 
General procedure for the synthesis of racemic and optically active sulfonamides 9a-e. Pyridine 
(56 L, 0.69 mmol) and p-toluensulfonyl chloride (134 mg, 0.70 mmol) were added to a solution of the 
corresponding amino alcohol 8a-e (0.54 mmol) in dry CH2Cl2 (13.5 mL). The solution was stirred at 
room temperature for 12 h until complete disappearance of the starting material was observed by TLC 
analysis. Almost all the solvent was removed by distillation under reduced pressure, and the resulting 
residue dissolved in EtOAc (20 mL) and washed firstly with an aqueous saturated NH4Cl solution (2 x 
20 mL), an aqueous HCl 1 M solution (2 x 20 mL) and finally an aqueous saturated NaCl solution (2 x 
20 mL). The organic phase was dried over Na2SO4, filtered and concentrated by distillation under 
reduced pressure. The crude was purified by column chromatography on silica gel (EtOAc/Hexane 
mixtures), affording the corresponding sulfonamides 9a-e (71-80%). 
 22 
N-(2-(2-Hydroxypropoxy)phenyl)-4-methylbenzenesulfonamide (9a). White solid (135 mg, 78% 
Yield). Rf (40% EtOAc/Hexane): 0.25. Mp: 166-167 ºC. IR (KBr): 3545, 3297, 3054, 2985, 2920, 2343, 
1596, 1501, 1404, 1340, 1156, 1114, 1088, 934, 819 cm-1. 1H NMR (300.13 MHz, (CD3)2CO):  1.13 
(d, 3JHH = 6.4 Hz, 3H), 2.34 (s, 3H), 3.61 (dd, 
2JHH = 9.4 Hz,
 3JHH = 7.6 Hz 1H), 3.71 (dd, 
2JHH = 9.4 Hz,
 
3JHH = 3.2 Hz, 1H), 3.90-4.03 (m, 1H), 4.50 (br s, 1H), 6.84-6.97 (m, 2H), 7.05 (td, 
3JHH = 7.8 Hz, 
4JHH 
= 1.7 Hz, 1H), 7.23-7.34 (m, 2H), 7.51 (dd, 3JHH = 7.8 Hz, 
4JHH = 1.6 Hz, 1H), 7.58-7.69 (m, 2H), 8.46 
(br s, 1H). 13C NMR (75.5 MHz, (CD3)2CO):  19.2 (CH3), 21.3 (CH3), 66.0 (CH), 75.4 (CH2), 113.4 
(CH), 121.7 (CH), 123.7 (CH), 126.6 (CH), 127.4 (C), 127.9 (2xCH), 130.1 (2xCH), 138.2 (C), 144.2 
(C), 151.0 (C). HRMS (ESI+, m/z): calcd for (C16H19NNaO4S)
+ (M+Na)+: 344.0927 found: 344.0941. 
[]D20 +15.1 (c 1.0, CHCl3) [for (S)-9a in >99% ee]. 
N-(5-Fluoro-2-(2-hydroxypropoxy)phenyl)-4-methylbenzenesulfonamide (9b). Colorless viscous 
oil (147 mg, 80% Yield). Rf (60% Et2O/Hexane): 0.14. IR (NaCl): 3342, 3054, 2986, 2934, 2362, 1616, 
1506, 1419, 1339, 1170, 1153, 1091, 1034, 812 cm-1. 1H NMR (300.13 MHz, (CD3)2CO):  1.15 (d, 
3JHH = 6.5 Hz, 3H), 2.34 (s, 3H), 3.61 (dd, 
2JHH = 9.5 Hz,
 3JHH = 7.6 Hz, 1H), 3.77 (dd, 
2JHH = 9.5 Hz,
 
3JHH = 3.0 Hz, 1H), 3.94-4.07 (m, 1H), 4.69 (br s, 1H), 6.78 (ddd, 
3JHH = 9.0 Hz, 
3JFH = 8.3 Hz,
 4JHH = 
3.1 Hz, 1H), 6.91 (dd, 3JHH = 9.0 Hz, 
4JFH = 5.1 Hz, 1H), 7.19-7.39 (m, 3H), 7.66-7.74 (m, 2H), 8.74 (br 
s, 1H). 13C NMR (75.5 MHz, (CD3)2CO):  19.1 (CH3), 21.3 (CH3), 66.0 (CH), 76.3 (CH2), 109.5 (d, 
2JFC = 27.8 Hz, CH), 111.6 (d, 
2JFC = 23.0 Hz, CH), 114.9 (d, 
3JFC = 9.4 Hz, CH), 127.9 (2xCH), 129.0 
(d, 3JFC = 11.0 Hz, C), 130.3 (2xCH), 137.8 (C), 144.6 (C), 146.8 (d, 
4JFC = 2.2 Hz, C), 157.6 (d, 
1JFC = 
237.0 Hz, C). HRMS (ESI+, m/z): calcd for (C16H18FNNaO4S)
+ (M+Na)+: 362.0833 found: 362.0847. 
[]D20 +16.0 (c 1.0, CHCl3) [for (S)-9b in >99% ee]. 
N-(2-(2-Hydroxypropoxy)-5-methoxyphenyl)-4-methylbenzenesulfonamide (9c). White solid (135 
mg, 71% Yield). Rf (40% EtOAc/Hexane): 0.18. Mp: 132-133 ºC. IR (KBr): 3339, 3054, 2935, 2356, 
1504, 1420, 1340, 1159, 1088, 956, 816 cm-1. 1H NMR (300.13 MHz, (CD3)2CO):  1.14 (d, 3JHH = 6.4 
Hz, 3H), 2.35 (s, 3H), 3.54 (dd, 2JHH = 9.6 Hz,
 3JHH = 7.7 Hz, 1H), 3.69-3.75 (m, 1H), 3.71 (s, 3H), 3.92-
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4.07 (m, 1H), 4.53 (d, 3JHH = 4.1 Hz, 1H), 6.58 (dd, 
3JHH = 8.9 Hz, 
4JHH = 3.0 Hz, 1H), 6.83 (d,
 3JHH = 
8.9 Hz, 1H), 7.13 (d, 4JHH = 3.0 Hz, 1H), 7.23-7.32 (m, 2H), 7.67-7.72 (m, 2H), 8.58 (br s, 1H). 
13C 
NMR (75.5 MHz, (CD3)2CO):  19.3 (CH3), 21.3 (CH3), 55.8 (CH3), 66.1 (CH), 76.7 (CH2), 108.9 
(CH), 110.2 (CH), 115.4 (CH), 128.1 (2xCH), 128.9 (C), 130.2 (2xCH), 138.1 (C), 144.4 (C), 144.6 (C), 
155.1 (C). HRMS (ESI+, m/z): calcd for (C17H21NNaO5S)
+ (M+Na)+: 374.1033 found: 374.1050. []D20 
+24.2 (c 1.0, CHCl3) [for (S)-9c in >99% ee]. 
N-(2-(2-Hydroxypropoxy)-4-methylphenyl)-4-methylbenzenesulfonamide (9d). Light pink solid 
(136 mg, 75% Yield). Rf (40% EtOAc/Hexane): 0.27. Mp: 139-141 ºC. IR (KBr): 3337, 3054, 2986, 
2928, 2307, 1596, 1507, 1419, 1339, 1164, 1123, 1092, 815 cm-1. 1H NMR (400.13 MHz, (CD3)2CO):  
1.14 (d, 3JHH = 6.5 Hz, 3H), 2.22 (s, 3H), 2.31 (s, 3H), 3.60 (dd, 
2JHH = 9.4 Hz,
 3JHH = 7.6 Hz, 1H), 3.67 
(dd, 2JHH = 9.4 Hz,
 3JHH = 3.2 Hz, 1H), 3.90-4.01 (m, 1H), 4.54 (d, 
3JHH = 4.2 Hz, 1H), 6.69-6.74 (m, 
2H), 7.23 (d, 3JHH = 8.1 Hz, 2H), 7.38 (d, 
3JHH = 7.8 Hz, 1H), 7.61 (d, 
3JHH = 8.3 Hz, 2H), 8.37 (br s, 
1H). 13C NMR (100.6 MHz, (CD3)2CO):  19.2 (CH3), 21.2 (CH3), 21.3 (CH3), 66.1 (CH), 75.1 (CH2), 
114.0 (CH), 122.1 (CH), 124.1 (CH), 124.6 (C), 127.9 (2xCH), 130.0 (2xCH), 136.6 (C), 138.2 (C), 
144.0 (C), 151.0 (C). HRMS (ESI+, m/z): calcd for (C17H21NNaO4S)
+ (M+Na)+: 358.1083 found: 
358.1096. []D20 +9.2 (c 1.0, CHCl3) [for (S)-9d in >99% ee]. 
N-(3,4-Difluoro-2-(2-hydroxypropoxy)phenyl)-4-methylbenzenesulfonamide (9e). Colorless 
viscous oil (154 mg, 80% Yield). Rf (40% EtOAc/Hexane): 0.41. IR (NaCl): 3349, 3054, 2986, 2359, 
1653, 1559, 1507, 1490, 1419, 1265, 1165, 1047, 896, 738, 705 cm-1. 1H NMR (300.13 MHz, CDCl3):  
1.20 (d, 3JHH = 6.4 Hz, 3H), 2.36 (s, 3H), 3.30 (br s, 1H), 3.59 (dd, 
2JHH = 10.3 Hz, 
3JHH = 8.1 Hz, 1H), 
3.93 (dd, 2JHH = 10.4 Hz, 
3JHH = 2.3 Hz, 1H), 4.04-4.18 (m, 1H), 6.83 (td, 
3JHH = 9.4 Hz,
 3JFH = 9.4, 
4JFH 
= 8.1 Hz, 1H), 7.22 (d, 3JHH = 8.2 Hz, 2H), 7.30 (ddd,
 3JHH = 9.4 Hz,
 4JFH = 5.2, 
5JFH = 2.4 Hz, 1H), 7.69 
(d, 3JHH = 8.3 Hz, 2H), 8.69 (br s, 1H). 
13C NMR (75.5 MHz, CDCl3):  19.0 (CH3), 21.7 (CH3), 66.7 
(CH), 79.8 (d, 4JFC = 3.6 Hz, CH2), 111.8 (d, 
2JFC = 18.1 Hz, CH), 116.5 (dd, 
3JFC = 11.4 Hz,
 4JFC = 3.8 
Hz, CH), 127.5 (2xCH), 127.9 (dd, 3JFC = 3.2 Hz,
 4JFC = 1.9 Hz, C), 129.8 (2xCH), 136.3 (C), 139.7 (dd, 
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2JFC = 10.6 Hz,
 3JFC = 2.0 Hz, C), 144.2 (C), 144.6 (dd, 
1JFC = 248.7 Hz,
 2JFC = 14.3 Hz, C), 148.4 (dd, 
1JFC = 247.0 Hz,
 2JFC = 11.1 Hz, C). HRMS (ESI
+, m/z): calcd for (C16H17F2NNaO4S)
+ (M+Na)+: 
380.0739 found: 380.0736. []D20 -21.5 (c 0.6, EtOH) [for (R)-9e in >99% ee]. 
 
General procedure for the synthesis of racemic and optically active tosylated benzoxazines 10a-
e. Triphenylphosphine (89 mg, 0.34 mmol) was added to a solution of the corresponding sulfonamide 
9a-e (0.28 mmol) in dry THF (3.1 mL). Next, diethyl azadicarboxylate (53 L, 0.34 mmol) was added 
dropwise and stirred at room temperature for 2 h. After this time, the solvent was removed by 
distillation under reduced pressure and the crude purified by column chromatography on silica gel 
(EtOAc/Hexane mixtures), affording the corresponding tosylated benzoxazines 10a-e (94-100%). 
3-Methyl-4-tosyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (10a). Colorless oil (84 mg, 99% Yield). Rf 
(40% EtOAc/Hexane): 0.72. IR (NaCl): 3054, 2986, 2340, 1599, 1559, 1490, 1350, 1170, 1072, 1015, 
815 cm-1. 1H NMR (300.13 MHz, CDCl3):  1.22 (d, 3JHH = 6.9 Hz, 3H), 2.38 (s, 3H), 3.20 (dd, 2JHH = 
11.1 Hz, 3JHH = 2.2 Hz, 1H), 3.79 (dd, 
2JHH = 11.1 Hz,
 3JHH = 1.3 Hz, 1H), 4.27-4.63 (m, 1H), 6.80 (d, 
3JHH = 8.0 Hz, 1H), 6.95 (t, 
3JHH = 7.7 Hz, 1H), 7.08 (t, 
3JHH = 7.6 Hz, 1H), 7.21 (dd, 
3JHH = 7.9 Hz, 
4JHH 
= 0.5 Hz, 2H), 7.46 (d, 3JHH = 7.9 Hz, 2H), 7.89 (d,
 3JHH = 8.0 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  
17.1 (CH3), 21.7 (CH3), 48.7 (CH), 66.1 (CH2), 117.2 (CH), 121.3 (CH), 122.0 (C), 126.1 (CH), 126.3 
(CH), 127.3 (2xCH), 130.0 (2xCH), 135.5 (C), 144.3 (C), 146.1 (C). HRMS (ESI+, m/z): calcd for 
(C16H17NNaO3S)
+ (M+Na)+: 326.0821 found: 326.0814. []D20 +164.8 (c 1.0, EtOH) [for (R)-10a in 
>99% ee]. 
6-Fluoro-3-methyl-4-tosyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (10b). White solid (85 mg, 94% 
Yield). Rf (60% EtOAc/Hexane): 0.64. Mp: 81-83 ºC. IR (KBr): 3054, 2987, 2929, 2341, 1616, 1597, 
1499, 1419, 1353, 1212, 1169, 970, 936, 814 cm-1. 1H NMR (300.13 MHz, CDCl3):  1.22 (d, 3JHH = 
6.9 Hz, 3H), 2.39 (s, 3H), 3.16 (dd, 2JHH = 11.1 Hz,
 3JHH = 2.6 Hz, 1H), 3.80 (dd, 
2JHH = 11.1 Hz,
 3JHH = 
1.5 Hz, 1H), 4.37-4.47 (m, 1H), 6.73-6.88 (m, 2H), 7.24 (d, 3JHH = 8.4 Hz, 2H), 7.51 (d, 
3JHH = 8.3 Hz, 
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2H), 7.69 (dd, 3JFH = 10.5 Hz, 
4JHH = 2.7 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  17.1 (CH3), 21.7 
(CH3), 48.8 (CH), 66.1 (CH2), 112.1 (d, 
2JFC = 27.7 Hz, CH), 113.0 (d, 
2JFC = 23.5 Hz, CH), 117.8 (d, 
3JFC = 9.0 Hz, CH), 122.5 (d, 
3JFC = 10.9 Hz, C), 127.3 (2xCH), 130.1 (2xCH), 135.3 (C), 142.1 (d, 
4JFC 
= 2.5 Hz, C), 144.5 (C), 156.8 (d, 1JFC = 238.2 Hz, C). HRMS (ESI
+, m/z): calcd for (C16H16FNNaO3S)
+ 
(M+Na)+: 344.0727 found: 344.0742. []D20 +171.7 (c 1.0, EtOH) [for (R)-10b in >99% ee]. 
6-Methoxy-3-methyl-4-tosyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (10c). White solid (88 mg, 94% 
Yield). Rf (40% EtOAc/Hexane): 0.66. Mp: 150-152 ºC. IR (KBr): 3734, 3054, 2986, 2360, 2342, 1761, 
1646, 1559, 1506, 1420, 1363, 1168, 933, 814 cm-1. 1H NMR (300.13 MHz, CDCl3):  1.22 (d, 3JHH = 
6.9 Hz, 3H), 2.37 (s, 3H), 3.12 (dd, 2JHH = 11.0 Hz,
 3JHH = 2.5 Hz, 1H), 3.74 (dd, 
2JHH = 11.0 Hz,
 3JHH = 
1.5 Hz, 1H), 3.80 (s, 3H), 4.34-4.50 (m, 1H), 6.66 (dd, 3JHH = 9.0 Hz, 
4JHH = 2.8 Hz, 1H), 6.72 (d,
 3JHH = 
8.9 Hz, 1H), 7.21 (d, 3JHH = 8.1 Hz, 2H), 7.44-7.54 (m, 3H). 
13C NMR (75.5 MHz, CDCl3):  17.1 
(CH3), 21.7 (CH3), 48.9 (CH), 55.9 (CH3), 65.9 (CH2), 109.8 (CH), 110.1 (CH), 117.6 (CH), 122.2 (C), 
127.3 (2xCH), 130.0 (2xCH), 135.4 (C), 140.1 (C), 144.3 (C), 153.7 (C). HRMS (ESI+, m/z): calcd for 
(C17H19NNaO4S)
+ (M+Na)+: 356.0927 found: 356.0944. []D20 +333.9 (c 1.0, EtOH) [for (R)-10c in 
>99% ee]. 
3,7-Dimethyl-4-tosyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (10d). Light brown viscous oil (88 mg, 
99% Yield). Rf (40% EtOAc/Hexane): 0.57. IR (NaCl): 3032, 2981, 2934, 2892, 2340, 1918, 1598, 
1577, 1500, 1349, 1321, 1219, 1167, 1069, 917, 813 cm-1. 1H NMR (300.13 MHz, CDCl3):  1.20 (d, 
3JHH = 6.9 Hz, 3H), 2.28 (s, 3H), 2.37 (s, 3H), 3.16 (dd, 
2JHH = 11.0 Hz,
 3JHH = 2.5 Hz, 1H), 3.75 (dd, 
2JHH = 11.1 Hz,
 3JHH = 1.4 Hz, 1H), 4.34-4.46 (m, 1H), 6.61 (d, 
4JHH = 1.2 Hz, 1H), 6.76 (dd, 
3JHH = 8.4 
Hz, 4JHH = 1.4 Hz, 1H), 7.21 (d, 
3JHH = 8.0 Hz, 2H), 7.46 (d, 
3JHH = 8.3 Hz, 2H), 7.75 (d, 
3JHH = 8.4 Hz, 
1H). 13C NMR (75.5 MHz, CDCl3):  17.1 (CH3), 21.0 (CH3), 21.7 (CH3), 48.7 (CH), 66.0 (CH2), 117.4 
(CH), 119.3 (C), 122.2 (CH), 125.9 (CH), 127.3 (2xCH), 129.9 (2xCH), 135.5 (C), 136.4 (C), 144.1 (C), 
145.9 (C). HRMS (ESI+, m/z): calcd for (C17H19NNaO3S)
+ (M+Na)+: 340.0978 found: 340.0990. []D20 
+210.1 (c c 1.0, EtOH) [for (R)-10d in >99% ee]. 
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7,8-Difluoro-3-methyl-4-tosyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (10e). White solid (95 mg, 
>99% Yield). Rf (30% EtOAc/Hexane): 0.42. Mp: 85-87 ºC. IR (KBr): 3054, 2987, 2343, 1598, 1508, 
1484, 1361, 1183, 1166, 1038, 815 cm-1. 1H NMR (400.13 MHz, CDCl3):  1.21 (d, 3JHH = 7.0 Hz, 3H), 
2.39 (s, 3H), 3.17 (dd, 2JHH = 11.1 Hz, 
3JHH = 2.6 Hz, 1H), 3.92 (dd,
 2JHH = 11.1 Hz, 
3JHH = 0.9 Hz, 1H), 
4.43-4.50 (m, 1H), 6.78 (td, 3JHH = 9.6 Hz,
 3JFH = 9.6, 
4JFH = 8.2, 1H), 7.24 (d,
 3JHH = 8.1 Hz, 2H), 7.44 
(d , 3JHH = 8.3 Hz, 2H), 7.64 (ddd, 
3JHH = 9.5 Hz,
 4JFH = 5.2, 
5JFH = 2.5 Hz, 1H). 
13C NMR (100.6 MHz, 
CDCl3):  17.0 (CH3), 21.7 (CH3), 48.3 (CH), 66.4 (CH2), 108.3 (d, 2JFC = 18.4 Hz, CH), 119.4 (d, 3JFC 
= 3.0 Hz, C), 120.4 (dd, 3JFC = 7.8 Hz,
 4JFC = 4.2 Hz,
 CH), 127.3 (2xCH), 130.2 (2xCH), 135.0 (C), 
136.7 (dd, 2JFC = 10.1 Hz,
 3JFC = 3.4 Hz, C), 140.0 (dd,
 1JFC = 247.4 Hz,
 2JFC = 15.6 Hz, C), 144.8 (C), 
148.6 (dd, 1JFC = 245.7 Hz,
 2JFC = 10.1 Hz, C). HRMS (ESI
+, m/z): calcd for (C16H15F2NNaO3S)
+ 
(M+Na)+: 362.0633, found: 362.0628. []D20 -183.2 (c 0.5, EtOH) [for (S)-10e in >99% ee]. 
 
General procedure for the synthesis of racemic and optically active benzoxazines 4a,e. 
Magnesium turnings (22 mg, 0.88 mmol) was added to a solution of the corresponding tosylated 
benzoxazine 10a,e (0.18 mmol) in dry MeOH (0.9 mL). The mixture was stirred under reflux for 2 h 
until complete deprotection of the tosyl group. Then, the solvent was removed by distillation under 
reduced pressure and the crude purified by column chromatography on silica gel (10% EtOAc/Hexane), 
affording the corresponding benzoxazines 4a,e (79-86%). 
3-Methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (4a). 21 mg, 79% Yield. Rf (10% EtOAc/Hexane): 
0.24. The spectroscopical data have been included previously in this experimental section. []D20 -17.6 
(c 0.5, CHCl3) [for (R)-4a in 99% ee]. [lit. []D20 -19 (c 1.3, CHCl3) for (S)-4a in 99% ee].8a 
7,8-Difluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (4e). 29 mg, 86% Yield. Rf (40% 
EtOAc/Hexane): 0.43. []D20 -8.6 (c 1.3, CHCl3) [for (S)-4e in 99% ee]. [lit. []D20 -9.1 (c 1.3, CHCl3) 
for (S)-4e in 99% ee].11c 
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Bioreduction of 1-(2-nitrophenoxy)propan-2-one (3a) with ADH-LK. In an eppendorf tube 
containing the ketone 3a (2.3 mg, 0.012 mmol) in a 50 mM TRIS.HCl buffer pH 7.5 (450 L), glucose-
6-phosphate (40 L), glucose-6-phosphate dehydrogenase (3 U, 10 L), 10 mM NADPH solution in 50 
mM TRIS.HCl buffer pH 7.5 (50 L) and ADH-LK (3 U, 2 mg) were successively added. The reaction 
was shaken at 250 rpm and 30 ºC for 24 h. Then, the mixture was extracted with EtOAc (2 x 500 L) 
and dried over Na2SO4, analyzing the reaction crude by NMR (conversion) and HPLC (enantiomeric 
excess). 
 
Bioreduction of 1-(2-nitrophenoxy)propan-2-one (3a) with ADH-CP. In an eppendorf tube 
containing the ketone 3a (2.3 mg, 0.012 mmol) in a 50 mM TRIS.HCl buffer pH 7.5 (450 L), 2-
propanol (25 L), a 10 mM NADH solution in 50 mM TRIS.HCl buffer pH 7.5 (50 L) and ADH-CP (3 
U, 7.5 L) were successively added. The reaction was shaken at 250 rpm and 30 ºC for 24 h. Then, the 
mixture was extracted with EtOAc (2 x 500 L) and dried over Na2SO4, analyzing the reaction crude by 
NMR (conversion) and HPLC (enantiomeric excess). 
 
Bioreduction of 1-(2-nitrophenoxy)propan-2-one (3a) with Baker′s yeast. Baker′s yeast (1.3 g) 
was added to a solution of glucose (165 mg) in H2O (11 mL) stirring the resulting suspension for 15 min 
at 30 ºC and 250 rpm. After this time, the ketone 3a (33 mg, 0.17 mmol) was added and the suspension 
was shaken at 30 ºC and 250 rpm for 24 h. Then, the reaction was centrifuged and the supernatant was 
extracted with EtOAc (3 x 20 mL). Organic layers were combined, dried over Na2SO4, filtered and the 
solvent was evaporated under reduced pressure, analyzing the reaction crude by NMR (conversion) and 
HPLC (enantiomeric excess). 
 
General procedure for the bioreduction of ketones 3a-e with ADH-LB. In an eppendorf tube 
containing the corresponding ketone 3a-e (0.018 mmol) and 2-propanol (38 L) in a 50 mM TRIS.HCl 
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buffer pH 7.5 (555 L), a 10 mM MgCl2 solution in 50 mM TRIS.HCl buffer pH 7.5 (75 L), a NADPH 
10 mM solution in 50 mM TRIS.HCl buffer pH 7.5 (75 L) and ADH-LB (4.5 U, 15 L) were 
successively added. The reaction was shaken at 30 ºC and 250 rpm for 24 h and then extracted with 
EtOAc (2 x 500L). Organic layers were combined and dried over Na2SO4, analyzing the reaction crude 
by NMR (conversion) and HPLC (enantiomeric excess). 
 
General procedure for the bioreduction of ketones 3a-e with ADH-A. In an eppendorf tube 
containing the corresponding ketone 3a-e (0.012 mmol) and 2-propanol (25 L) in a 50 mM TRIS.HCl 
buffer pH 7.5 (425 L), a NADH 10 mM solution in 50 mM TRIS.HCl buffer pH 7.5 (50 L) and E. 
coli/ADH-A cells (15 mg) were successively added. The reaction was shaken at 30 ºC and 250 rpm for 
24 h. After this time, the mixture was extracted with EtOAc (2 x 500 L), the organic layers combined 
and dried over Na2SO4, analyzing the reaction crude by NMR (conversion) and HPLC (enantiomeric 
excess). 
 
General procedure for the bioreduction of ketones 3a-e with evo-1.1.200. In an eppendorf tube 
containing the corresponding ketone 3a-e (0.015 mmol) and 2-propanol (25 L) in 50 mM TRIS.HCl 
buffer pH 7.5 (400 L), a 10 mM MgCl2 solution in 50 mM TRIS.HCl buffer pH 7.5 (60 L), a 10 mM 
NADH solution in 50 mM TRIS.HCl buffer pH 7.5 (60 L) and evo-1.1.200 (60 L of a solution 
composed by 1 mg of pure evo-1.1.200 in 760 L of a 50 mM TRIS.HCl buffer pH 7.5 and 240 L of a 
10 mM MgCl2 solution) were successively added. The reaction was shaken at 30 ºC and 250 rpm for 24 
h. Then, the mixture was extracted with EtOAc (2 x 500 L), the organic layers combined and dried 
over Na2SO4, analyzing the reaction crude by GC (conversion) and HPLC (enantiomeric excess). For 
the ketone 3e better results were found at slight acid pHs (6-6.5), suppressing the appearance of the 
side-product 11 at an optimal pH 6 value. 
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General procedure for the scale up of bioreduction of ketones 3a-e with ADH-A. E. coli/ADH-A 
cells (ratio 20:1 in weight ketone/crude enzyme) were rehydrated in a 50 mM TRIS.HCl buffer pH 7.5 
(22 mL) by shaking the mixture at 30 ºC and 250 rpm for 5 min. The corresponding ketones 3a-e (0.94 
mmol), 2-propanol (1.5 mL) and NADH (10 mg) were successively added. The suspension was shaken 
at 30 ºC and 250 rpm until no starting material was detected by TLC analysis (24 h). Then, the mixture 
was extracted with EtOAc (3 x 20 mL), combining the organic layers, which were dried over Na2SO4, 
filtered and the solvent removed under reduced pressure, affording the corresponding alcohols (S)-5a-e 
(85-93%, 99% ee). 
 
General procedure for the scale up of bioreduction of ketones 3a-e with evo-1.1.200. To a 
suspension of ketone 3a-e (0.15 mmol) in a mixture of 2-propanol (250 L) and a 50 mM TRIS.HCl 
buffer pH 7.5 (4 mL), a 10 mM MgCl2 solution in 50 mM TRIS
.HCl buffer pH 7.5 (600 L), a 10 mM 
NADH solution in 50 mM TRIS.HCl buffer pH 7.5 (600 L) and evo-1.1.200 (600 L of a solution 
composed by 1 mg of pure evo-1.1.200 in 760 L of a 50 mM TRIS.HCl buffer pH 7.5 and 240 L of a 
10 mM MgCl2 solution) were successively added. The reaction was shaken at 30 ºC and 250 rpm for 24 
h. The mixture was extracted with EtOAc (3 x 10 mL), the organic layers were combined, dried over 
Na2SO4, filtered and the solvent removed under reduced pressure, affording the corresponding alcohol 
(R)-5a-e (78-99% yield, >99% ee). As mentioned before, for the ketone 3e better results were found at 
slight acid pHs (6-6.5), suppressing the appearance of the side-product 11 at an optimal pH 6 value. 
 
General procedure for the enzymatic kinetic resolution by acylation of racemic alcohols 5a-e. 
Vinyl acetate (7, 140 L, 1.52 mmol) and RML IM (ratio 1:1 in weight alcohol/enzyme) were added to 
a suspension containing the corresponding racemic alcohol 5a-e (0.51 mmol) in dry MTBE (5.1 mL) 
under nitrogen atmosphere. The reaction was shaken at 30 ºC and 250 rpm for the necessary time to 
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achieve a good kinetic resolution (see Tables 1 and S1). The reaction was followed by HPLC analysis 
until around 50% conversion was reached. The enzyme was filtered off, washed with CH2Cl2 (3 x 5 mL) 
and the solvent evaporated under reduced pressure. The crude reaction was purified by column 
chromatography on silica gel (eluent gradient 20-40% EtOAc/Hexane), affording the corresponding 
optically active acetates (R)-6a-e (45-47% yield, 93-95% ee) and alcohols (S)-5a-e (44-48% yield, 89-
94% ee). 
 
General procedure for the enzymatic kinetic resolution by hydrolysis of racemic acetates 6a-e. 
Water (39 L, 2.16 mmol) was added to a suspension containing the corresponding racemic acetate 6a-e 
(0.43 mmol) and RML IM (ratio 1:1 in weight acetate/enzyme) in MTBE (4.3 mL). The reaction was 
shaken at 30 ºC and 250 rpm for the necessary time to achieve a good kinetic resolution (see Table 2). 
The reaction was followed by HPLC analysis until around 50% conversion was reached. The enzyme 
was filtered off, washed with CH2Cl2 (3 x 5 mL) and the solvent was evaporated under reduced 
pressure. The crude reaction was purified by column chromatography on silica gel (eluent gradient 20-
40% EtOAc/Hexane), affording the corresponding optically active alcohols (R)-5a-e (44-47% yield, 96-
>99% ee) and acetates (S)-6a-e (41-48% yield, 91-97% ee). 
 
The following optical rotation values of alcohols 5a-e and acetates 6a-e were found after selected 
biocatalyzed transformations: (S)-5a: []D20 +6.0 (c 0.6, EtOH) (>99% ee); (S)-5b: []D20 +7.0 (c 0.5, 
EtOH) (>99% ee); (S)-5c: []D20 +4.0 (c 0.75, EtOH) (>99% ee); (S)-5d: []D20 +3.2(c 0.65, EtOH) 
(>99% ee); (R)-5e: []D20 -4.8 (c 0.4, EtOH) (>99% ee); (S)-6a: []D20 -74.3 (c 1.0, CHCl3) (93% ee); 
(R)-6b: []D20 -58.8 (c 0.75, CHCl3) (91% ee); (S)-6c: []D20 -49.7 (c 0.7, CHCl3) (80% ee); (S)-6d: 
[]D20 -63.8 (c 0.8, CHCl3) (85% ee); (S)-6e: []D20 -18.5 (c 0.6, CHCl3) (63% ee). 
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